Compare WFRD & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFRD | RYTM |
|---|---|---|
| Founded | 1941 | 2008 |
| Country | United States | United States |
| Employees | 19000 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | N/A | 2017 |
| Metric | WFRD | RYTM |
|---|---|---|
| Price | $83.90 | $102.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $93.22 | ★ $128.54 |
| AVG Volume (30 Days) | ★ 1.1M | 658.3K |
| Earning Date | 02-03-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.52 | N/A |
| Revenue | ★ $4,970,000,000.00 | $174,334,000.00 |
| Revenue This Year | N/A | $47.34 |
| Revenue Next Year | N/A | $55.95 |
| P/E Ratio | $15.16 | ★ N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $36.74 | $45.91 |
| 52 Week High | $91.23 | $122.20 |
| Indicator | WFRD | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 45.21 |
| Support Level | $85.57 | $96.20 |
| Resistance Level | $88.71 | $114.00 |
| Average True Range (ATR) | 2.74 | 5.41 |
| MACD | -0.25 | -0.06 |
| Stochastic Oscillator | 47.19 | 33.31 |
Weatherford provides oilfield services and equipment to national, integrated, public, and private oil and gas operators. It operates across multiple upstream markets, including offshore, the rest of the world onshore, and US onshore, where Weatherford has limited exposure. The Middle East, North Africa, and Asia account for over 25% of sales. Weatherford also offers manufacturing, research, and training services. Performance is reported through three segments: drilling and evaluation, well construction and completions, and production and intervention.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.